Famotidine
- 1 January 1990
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 18 (1) , 77-81
- https://doi.org/10.2165/00003088-199018010-00005
Abstract
The pharmacokinetic and pharmacodynamic properties of the H2-receptor antagonist famotidine have been well described in adult subjects. However, similar data for children are not available. Therefore, this study looked at the disposition of the drug (given to prevent aspiration following cardiac surgery) in 10 paediatric patients with normal kidney function (age range 2 to 7 years, bodyweight 14 to 25kg) after a single intravenous dose of famotidine 0.3 mg/kg. Plasma concentrations of the drug and gastric pH values were both monitored for 20 hours by high performance liquid chromatography and aspiration of gastric juice, respectively. Plasma famotidine concentrations declined with an elimination half-life of 3.3 ± 1.8h (mean ± SD) and the drug was effective in elevating the gastric pH above 3.5 for about 9 hours in 6 patients. The variable volume of distribution and total plasma clearance of famotidine averaged 1.4 ± 1.0 L/kg and 0.3 ±0.17 L/h/kg, respectively. In 4 patients unchanged famotidine could also be measured in a 12-hour urine fraction. The amount excreted (21 to 79%) correlated with clearance (r = 0.97). All these data are comparable to those obtained in healthy adults, indicating that paediatric patients receiving intensive medical treatment after cardiac surgery can handle famotidine in a way very similar to healthy adult subjects. A dosage of 0.3 mg/kg every 8 hours appears to be advisable.This publication has 16 references indexed in Scilit:
- Pharmacokinetics of Ranitidine in Critically Ill InfantsDevelopmental Pharmacology and Therapeutics, 1989
- Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjectsClinical Pharmacology & Therapeutics, 1988
- Newer H2-Receptor AntagonistsClinical Pharmacokinetics, 1988
- Pharmacokinetics and dynamics of famotidine in patients with renal failure.British Journal of Clinical Pharmacology, 1988
- The Altered Pharmacokinetics and Pharmacodynamics of Drugs Commonly Used in Critically III PatientsClinical Pharmacokinetics, 1988
- Effects of antacids and food on absorption of famotidine.British Journal of Clinical Pharmacology, 1987
- PHARMACOKINETICS OF FAMOTIDINE IN MAN1987
- FamotidineDrugs, 1986
- Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal functionEuropean Journal of Clinical Pharmacology, 1985
- Inhibition of gastric secretion by a new H2-antagonist, YM-11170 in healthy subjects.1984